- Home
- ZBAI vs PHIO Comparison
ZBAI vs PHIO Comparison
Compare ZBAI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- PHIO
- Stock Information
- Founded
- ZBAI 2015
- PHIO 2011
- Country
- ZBAI United States
- PHIO United States
- Employees
- ZBAI N/A
- PHIO N/A
- Industry
- ZBAI Professional Services
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- PHIO Health Care
- Exchange
- ZBAI Nasdaq
- PHIO Nasdaq
- Market Cap
- ZBAI 11.3M
- PHIO 12.1M
- IPO Year
- ZBAI N/A
- PHIO N/A
- Fundamental
- Price
- ZBAI $8.79
- PHIO $2.07
- Analyst Decision
- ZBAI
- PHIO Strong Buy
- Analyst Count
- ZBAI 0
- PHIO 3
- Target Price
- ZBAI N/A
- PHIO $10.67
- AVG Volume (30 Days)
- ZBAI 90.7K
- PHIO 70.0K
- Earning Date
- ZBAI 12-18-2025
- PHIO 11-13-2025
- Dividend Yield
- ZBAI N/A
- PHIO N/A
- EPS Growth
- ZBAI N/A
- PHIO N/A
- EPS
- ZBAI N/A
- PHIO N/A
- Revenue
- ZBAI $720,000.00
- PHIO N/A
- Revenue This Year
- ZBAI N/A
- PHIO N/A
- Revenue Next Year
- ZBAI N/A
- PHIO N/A
- P/E Ratio
- ZBAI N/A
- PHIO N/A
- Revenue Growth
- ZBAI 44.00
- PHIO N/A
- 52 Week Low
- ZBAI $4.83
- PHIO $0.97
- 52 Week High
- ZBAI $45.00
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- ZBAI 53.29
- PHIO 40.80
- Support Level
- ZBAI $7.98
- PHIO $2.08
- Resistance Level
- ZBAI $8.95
- PHIO $2.17
- Average True Range (ATR)
- ZBAI 0.71
- PHIO 0.10
- MACD
- ZBAI -0.10
- PHIO -0.01
- Stochastic Oscillator
- ZBAI 37.28
- PHIO 11.76
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.